02326nas a2200361   4500000000100000008004100001260001300042653001600055653002900071653001200100653003100112653003000143653001100173653001000184653002300194653001200217653001300229653003500242100001100277700001300288700001300301700001200314700001200326700001200338700001300350700001200363700008400375245008100459300001200540490000700552520139100559022001401950       2006                            d  c2006 Sep10aClofazimine10aCongenital Abnormalities10aDapsone10aDrug Resistance, Microbial10aDrug Therapy, Combination10aHumans10aJapan10aLeprostatic Agents10aleprosy10aRifampin10aSurgical Procedures, Operative1 aGoto M1 aNogami R1 aHatano K1 aOkano Y1 aIshii N1 aGidoh M1 aIshida Y1 aOzaki M1 aad hoc committee on treatment guideline and judgment of cure, Japanese Leprosy 00a[Guideline for the treatment of Hansen's disease in Japan (Second edition)].  a191-2260 v753 a<p>ad hoc committee of Japanese Leprosy Association recommends revised standard treatment protocol of leprosy in Japan, which is a modification of World Health Organization's multidrug therapy (WHO/MDT, 1997). For paucibacillary (PB) leprosy, 6 months treatment by rifampicin and dapsone (MDT/PB) is enough. However, for high bacterial load multibacillary (MB) leprosy, 12 months treatment seems insufficient. Thus, (A) For MB with bacterial index (BI) > or = 3 before treatment, 2 years treatment by rifampicin, dapsone and clofazimine (MDT/MB) is necessary. When BI become negative and active lesion is lost within 2 years, no maintenance therapy is necessary. When BI is still positive, one year of MDT/MB is added (3 years in total), followed by maintenance therapy by dapsone and clofazimine until BI negativity and loss of active lesions. (B) For MB with BI < 3 or fresh MB (less than 6 months after the onset of the disease) with BI > or = 3, 1 year treatment by MDT/MB is necessary. When BI become negative and active lesion is lost within one year, no maintenance therapy is necessary. When BI is still positive or active lesion is remaining, additional therapy with MDT/MB for one more year is recommended. This is a simplification of first version in 2000. Brief summary of diagnosis, purpose of therapy, character of drugs, and prevention of deformity is also described.</p>  a1342-3681